Cytogen Inc (217330.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7217330000

Price
2,315.00 KRW
Market cap
53.54 bn KRW
P/E (2025)
–
P/S (2025)
2.05
Dividend yield
0.00 %
Net margin
-47.37 %
Return on equity (ROE)
-34.71 %
Return on assets (ROA)
-19.83 %

Cytogen Inc financials

Fiscal year20242025
Revenue10.91 bn KRW26.05 bn KRW
Gross profit2.83 bn KRW5.61 bn KRW
Operating income-14.03 bn KRW-7.48 bn KRW
EBIT-15.84 bn KRW-10.62 bn KRW
Net income-17.12 bn KRW-12.34 bn KRW
Diluted EPS – continuing operations-741.97 KRW-533.70 KRW

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Cytogen Inc

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.